American Regent vs. Zydus: Selenious Acid Patent Consolidated Into Multi-Defendant ANDA Litigation

Case Overview

The Parties

The Patent at Issue

The asserted patent, U.S. Patent No. US12150957B2 (Application No. US18/672876), covers ARI’s selenious acid formulations. Selenious acid serves as a critical selenium source in intravenous trace element preparations. The patent’s claims are directed toward specific formulations and concentrations of selenious acid solutions intended for parenteral administration, protecting ARI’s proprietary product line from generic competition.

• • US12150957B2 — Selenious acid formulations for parenteral administration.

The Accused Products

ARI alleged that Zydus’ selenious acid intravenous solutions — formulated at (1) 12 mcg/2 mL, (2) 60 mcg/mL, and (3) 600 mcg/10 mL — infringe the claims of US12150957B2. These three concentrations mirror ARI’s own marketed product specifications: (1) eq. 600 mcg Selenium/10 mL, (2) eq. 60 mcg Selenium/mL, and (3) eq. 12 mcg Selenium/2 mL — a direct product-to-product correspondence typical of ANDA pharmaceutical patent disputes.

Legal Representation

ARI was represented by Charles H. Chevalier and Christine A. Gaddis of Gibbons PC, a prominent New Jersey-based firm with deep pharmaceutical patent litigation experience. Defendant agent and law firm information for Zydus were not disclosed in the available case record.

Litigation Timeline & Procedural History

The 21-day case duration from filing to consolidation reflects a purely procedural resolution at this stage — the substantive infringement claims remain live within the consolidated proceeding. The venue selection of the District of New Jersey is strategically significant: New Jersey is one of the nation’s premier forums for Hatch-Waxman ANDA litigation given its proximity to major pharmaceutical manufacturers, experienced patent judiciary, and established local rules favorable to efficient IP case management.

The consolidated action was assigned to Judge Brian R. Martinotti (BRM) with Magistrate Judge Cathy L. Waldor (CLW), a pairing with demonstrated experience managing complex multi-party pharmaceutical patent proceedings.

The Verdict & Legal Analysis

Outcome

Case No. 2:24-cv-11133 was formally closed on January 3, 2025, upon consolidation into the lead docket, In re Selenious Acid Litigation (No. 2:24-cv-7791). The basis of termination was case consolidation — not a merits determination. No damages award, injunctive relief ruling, or validity finding has been issued at this stage. The substantive infringement dispute between ARI and Zydus continues within the consolidated framework.

Verdict Cause Analysis

The infringement action arises under the Hatch-Waxman Act framework, wherein ARI’s filing of suit within 45 days of receiving notice of Zydus’ Abbreviated New Drug Application (ANDA) triggers an automatic 30-month stay of FDA approval for Zydus’ generic selenious acid products. This mechanism — codified under 21 U.S.C. § 355(j)(5)(B)(iii) — is the central strategic driver of coordinated same-day filings against multiple ANDA applicants.

By filing simultaneously against all twelve generic applicants on December 13, 2024, ARI ensured that each defendant is subject to a coordinated discovery and claim construction schedule within the consolidated proceeding, maximizing ARI’s litigation efficiency while imposing proportional defense costs across the generic field.

The three-concentration product matrix — 12 mcg/2 mL, 60 mcg/mL, and 600 mcg/10 mL — alleged against Zydus mirrors the accused product specifications across all twelve defendants, suggesting that the ANDA filers sought FDA approval for products designed to be therapeutically and commercially interchangeable with ARI’s entire selenious acid line.

Legal Significance

This consolidation establishes In re Selenious Acid Litigation as a hub proceeding for trace element intravenous formulation patent law. Key legal questions likely to be litigated going forward include:

• • Claim construction of the concentration parameters and formulation limitations in US12150957B2
• • Obviousness challenges under 35 U.S.C. § 103, given that selenious acid is a well-characterized pharmaceutical compound with prior art formulations
• • Written description and enablement challenges under 35 U.S.C. § 112, particularly whether the patent’s claims adequately support the full scope of the selenious acid formulations asserted
• • Non-infringement arguments by generic defendants potentially centered on formulation differences, excipient variations, or manufacturing process distinctions

Strategic Takeaways

For Patent Holders: ARI’s coordinated same-day multi-defendant filing is a textbook ANDA enforcement strategy. Filing simultaneously ensures uniform 30-month stay protections across all ANDA applicants, prevents any single generic from achieving first-filer market exclusivity advantages, and enables consolidated litigation economics. Patent holders in specialty pharmaceutical and parenteral nutrition spaces should structure prosecution strategies to ensure concentration-range and formulation claims are drafted with sufficient specificity to withstand § 103 challenges while covering commercially viable generic product profiles.

For Accused Infringers (Generic Manufacturers): Consolidated proceedings create both risks and efficiencies for defendants. Shared claim construction briefing can reduce individual costs, but also means adverse rulings bind all defendants simultaneously. Zydus and co-defendants should evaluate whether inter partes review (IPR) petitions at the USPTO Patent Trial and Appeal Board (PTAB) against US12150957B2 offer a viable parallel challenge track to district court litigation.

For R&D Teams: Generic pharmaceutical developers entering the parenteral nutrition space should conduct rigorous freedom-to-operate (FTO) analyses covering the full selenious acid patent family before ANDA submission. The multi-concentration nature of ARI’s product line — and the breadth of the patent’s apparent coverage — signals that design-around strategies limited to single concentration modifications may be insufficient.

Industry & Competitive Implications

The In re Selenious Acid Litigation consolidation is significant for the parenteral nutrition and intravenous trace element market, an estimated multi-hundred-million-dollar segment critical to hospital formularies nationwide. Selenium deficiency in TPN patients carries serious clinical consequences, making uninterrupted generic supply a public health concern alongside commercial competition.

The breadth of ARI’s enforcement action — twelve defendants across Accord, Aspiro, Cipla, Dr. Reddy’s, Gland Pharma, Hikma, RK Pharma, Somerset/Odin, Sun Pharma, Xiromed, and Zydus — indicates that ARI views its selenious acid patent as a robust exclusivity asset warranting full-field enforcement. This approach mirrors enforcement patterns seen in other specialty injectable drug categories, where branded manufacturers use coordinated ANDA litigation to protect niche but high-margin hospital formulary products.

For generic manufacturers operating in the parenteral nutrition space, the consolidation signals that entry strategies must account for potential patent litigation costs across multiple ANDA product lines simultaneously. Licensing negotiations or settlement discussions with ARI may emerge as the consolidated proceeding advances through claim construction.